Business Wire

TX-FLUENCE

11.8.2022 14:32:09 CEST | Business Wire | Press release

Share
Fluence and REMY LED Lighting Collaboration Flourishes at Leading Israeli Cannabis Farms

Fluence Bioengineering, Inc. (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, in collaboration with REMY, a horticultural lighting provider to Israel’s growing agriculture industry, is supporting the record introduction of lighting technology solutions to Israel’s medical cannabis facilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005211/en/

Israel—considered a world leader in cannabis research, cultivation and advanced regulation—has positioned itself at the forefront of the $74 trillion global cannabis market through highly innovative technology and data applications. The country now boasts supply capabilities that surpass its domestic demand. As the Israeli market matures, more and more indoor farms are capitalizing on leading controlled environment agriculture strategies proven to optimize plant growth and profits.

REMY’s expertise, paired with Fluence’s products and evidence-based best practices for optimal lighting strategies at each phase of cannabis growth, has placed the companies’ collaborative designs in the three core categories of medical cannabis facilities in Israel: greenhouse, indoor and vertical farms.

Hybrid cultivation at Green Fields

Green Fields, which operates the largest medical cannabis growing facility in Israel, features a hybrid greenhouse model of harnessing sunlight and supplementing with artificial lighting to optimize plant quality. The forward-looking company chose Fluence and REMY to install a high-intensity lighting system.

"After working on several projects with REMY, we know the value of their professionalism, expertise and service. That's why we chose them for our flagship project," explained Jonathan Pisso, chief procurement officer of Green Fields. "The difference we saw in the first crop cycle using Fluence lighting was phenomenal. As a result of the facility's control system, we have a great deal of flexibility and maximum control. We have integrated all the technologies with an extremely powerful lighting system, which results in uniform growth and excellent results."

Growing indoors with Springs Valley Cannabis

Another popular type of cannabis facility in Israel is the fully indoor model, which allows control of all crop conditions to ensure uniform growth throughout the year while maximizing quality. Springs Valley Cannabis is setting up to become a major cannabis cultivator in Israel. It elected to use Fluence and REMY for lighting solutions in its indoor facility that covers an impressive 5,000 square meters of canopy.

"When we designed our unique facility, we sought trustworthy partners who would ensure our product would be a market leader. We found it in the combination of Fluence and REMY," said Yossi Shitrit, founder of Springs Valley Cannabis.

Trichome’s urban vertical farm

Located in the heart of an urban industrial area, Trichome operates a fully indoor, multi-tier vertical farming facility. Harnessing the power and control of indoor cultivation methods, Trichome searched for industry-leading partners with experience optimizing environmental parameters in a multi-tier environment. With Fluence’s SPYDR Series, Trichome leverages a high intensity, broad-spectrum strategy that delivers precise and uniform light to the plant canopy.

"Fluence’s and REMY's teams are extremely professional. They are dedicated to our success and bring us added value. The results are already exceeding our initial expectations," said Tony Levi, founder and CEO at Trichome. "It shows the potential for indoor growth in urban centers. The facility utilizes every square meter of the building for efficiency and uniformity."

"Israel is a technological 'playground' for the cannabis market, which makes it easy to examine and adopt advanced technologies quickly," said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. "With the early-adapter frame of mind that the Israeli industry practices, Fluence has managed to deliver expert horticulture knowledge and, together with REMY, cooperate with leading innovative growers to advance their operations."

In addition to providing lighting solutions, REMY specializes in the planning, installation, integration and quality assurance of large-scale agronomic solutions, as well as after-sales service and support.

"At the end of the day, the plant is the best indication for our success or failure—and we are achieving success in multiple, diverse cultivation environments," said Elad Toby, founder, CTO and chief business development officer for REMY.

To learn more about REMY, click here . To learn more about Fluence’s portfolio of luminaires and lighting controls, visit the company’s website here .

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .

About REMY

Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye